BCL2 mutations do not confer adverse prognosis in follicular lymphoma patients treated with rituximab.
Fiche publication
Date publication
mars 2017
Journal
American journal of hematology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr FEUGIER Pierre
Tous les auteurs :
Huet S, Szafer-Glusman E, Tesson B, Xerri L, Fairbrother WJ, Mukhyala K, Bolen C, Punnoose E, Tonon L, Chassagne-Clément C, Feugier P, Viari A, Jardin F, Salles G, Sujobert P
Lien Pubmed
Résumé
BCL2 mutations have been suggested to confer an adverse prognosis to follicular lymphoma (FL) patients, but their prognostic value has not been assessed in patients treated with a rituximab-containing regimen. Here we evaluated the prognostic value of BCL2 mutations in a large prospective cohort of 252 patients with FL treated with immunochemotherapy in the PRIMA randomized trial. Using a DNA-targeted sequencing approach, we detected amino acid altering mutations in 135 patients (54%) and showed that these mutations were probably mediated by the over-activation of AICDA (activation-induced cytidine deaminase) in the context of the t(14;18) translocation. The BCL2 variants identified in PRIMA patients affected the BH1, BH2, and BH3 functional motifs at a lower frequency than the N-terminus and flexible loop domain, with mostly conservative aminoacid changes. With a median follow-up of 6.7 years, we did not observe any impact of BCL2 mutations either on overall survival or progression-free survival.
Mots clés
Antineoplastic Agents, therapeutic use, Female, Humans, Lymphoma, Follicular, drug therapy, Male, Mutation, Prognosis, Proto-Oncogene Proteins c-bcl-2, genetics, Rituximab, therapeutic use, Translocation, Genetic, Treatment Outcome
Référence
Am. J. Hematol.. 2017 Mar;: